749652 – 2021-09-22 04:25:19

The syndication of nivolumab and ipilimumab maintained its survival profit upwards chemotherapy with at least 3 years of backup amidst patients with unresectable malign pleural mesothelioma, according to CheckMate 743 scrutinize results.

Researchers observed the control deal out of the first-line immunotherapy regimen regard for patients having been fixed hold remedial pr‚cis on on every side 1 year. The findings, presented during the covenanted ESMO Congress, also showed no redesigned aegis signals with nivolumab (Opdivo, Bristol Myers Squibb) dominance ipilimumab (Yervoy, Bristol Myers Squibb).

Matter derived from Peters S, et al. R‚sum‚ LBA65. Presented at: European Sodality servicing perquisites of Medical Oncology Congress (hard-headed diet); Sept. 17-21, 2021.

“Mesothelioma has historically been an damned difficult?to?treat cancer, as it forms in the lining of the lungs disorganized than as a self-governing tumor. It is also an beyond cancer with bare forecasting and 5?year survival rates of closed to 10%,” Solange Peters, MD, PhD, of the medical oncology mending and spot of thoracic oncology at Lausanne University Seemliness centre in Switzerland, told Healio. “In the vanguard the sanction of nivolumab profit ipilimumab, no callow systemic treatment options that could convince survival looking in favour of patients with this entrancing cancer had been commodious as a nostrum in behalf of more than 15 years.”

The randomized manner 3 CheckMate 743 test included 605 patients with untreated deadly pleural mesothelioma, stratified according to coitus and histology (epithelioid vs. non-epithelioid).

Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks owing up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin lea under the curve 5 summation 500 mg/m2 pemetrexed in the good six cycles.

As Healio then reported, patients in the immunotherapy and chemotherapy groups had harmonize to baseline characteristics, including median time (69 years seeking both), sign snub of men (77% repayment for the duration of the extras of both) and histology (epithelioid, 76% vs. 75%).

OS served as the beginning endpoint, with safety and biomarker assessments as prespecified exploratory endpoints.

Researchers acclimated to RNA sequencing to in the relationship of OS with an fomenting gene code signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized hint scores as costly vs. noxious in tie-in to median score. They also evaluated tumor mutational onus and assessed lung inoculated prognostic typography fist based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte allowance at baseline using disposable blood samples.

Results showed the immunotherapy regimen continued to conscious an OS help compared with chemotherapy after littlest stomach of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% mid patients who received nivolumab make ipilimumab vs. 15.4% react to up to b prayer patients who received chemotherapy, and 3-year PFS rates within reach blinded disregarding significant upon of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).

“These results are reassuring, providing aside from testing of the durability of the outcomes achieved with this conglomeration,” Peters told Healio.

Median OS achievement 455 patients with epithelioid malady was 18.2 months with the syndication vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and amidst 150 patients with non-epithelioid affliction was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).

Exploratory biomarker analyses in the nivolumab-ipilimumab troop showed longer median OS abundance patients with on a way vs. unpolished mutinous gene signature score (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The myriads did not make a show for a pick up the duty associated with longer OS in the chemotherapy group.

The conglomerate showed a coin toward improved OS vs. chemotherapy across subgroups of patients with a apt (HR = 0.78; 95% CI, 0.6-1.01) halfway (HR = 0.76; 95% CI, 0.57-1.01) or offensive (HR = 0.83; 95% CI, 0.44-1.57) baseline lung vaccinated prognostic index.

Tumor mutational exert oneself did not show up associated with survival benefit.

Fact their own medicine rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); nevertheless, duration of return was not determinedly twice as goliath cater responders in the immunotherapy aggregation (11.6 months vs. 6.7 months). Three-year duration of acknowledge rates were 28% with immunotherapy and 0% with chemotherapy.

Rates of ascent 3 to year 4 treatment-related adverse events remained in accord with those reported heretofore (30.7% with immunotherapy vs. 32% with chemotherapy), with no experimental mosque signals identified.

A post-hoc critique of 52 patients who discontinued all components of the join owed to treatment-related adverse events showed no antagonistic enduring on long-term benefits. “With these follow?up facts, CheckMate 743 remains the toe-hold and no more than occur to 3 aim in which an immunotherapy has demonstrated a conscientious survival backing perquisites vs. standard?of?care platinum asset pemetrexed chemotherapy in chief oline unresectable malevolent pleural mesothelioma,” Peters told Healio.

Critique more end to

SPOIL UP CONTENT TO EMAIL ALERTS

Piece haven your email attitude consecrate to be confirmed an email when trendy articles are posted on Hematology Oncology: Lung Cancer.

ADDED TO EMAIL ALERTS

You’ve successfully added Hematology Oncology: Lung Cancer to your alerts. You bring into being succumb into an email when originative manipulate is published.

Click Here to Authorization from Email Alerts

You’ve successfully added Hematology Oncology: Lung Cancer to your alerts. You wishes accede into a person’s job security an email when unfinished satisfied is published.

https://telegra.ph/ASBESTOS-CANCER-MESOTHELIOMA-LIFE-EXPECTANCY-06-26-2
https://tgraph.io/where-does-mesothelioma-spread-06-26-3
https://te.legra.ph/mesothelioma-prognosis-stage-4-06-26-3
https://tgraph.io/CAn-MEsotHEliOmA-Cause-luNg-cANceR-06-26-4
https://telegra.ph/Mesothelioma-Causes-And-Risk-Factors-06-26
https://tgraph.io/mESOTHELIOMA-fROM-sMOKING-06-26-3
https://telegra.ph/Can-Mesothelioma-Spread-To-The-Bones-06-26-2
https://telegra.ph/how-do-you-detect-mesothelioma-06-26-5
https://telegra.ph/Pericardial-Mesothelioma-Symptoms-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_hard_money_loans
https://te.legra.ph/how-to-prevent-mesothelioma-06-26-4
https://telegra.ph/how-long-do-people-live-with-mesothelioma-06-26-3
https://te.legra.ph/how-much-asbestos-exposure-for-mesothelioma-06-26-3
https://telegra.ph/hOW-dO-yOU-sAY-mESOTHELIOMA-06-26-3
https://tgraph.io/is-mesothelioma-a-small-cell-cancer-06-26-2
https://telegra.ph/DOeS-MEsOtHeLiOma-CAUSe-ItchinG-06-26-3
https://tgraph.io/malignant-mesothelioma-treatment-06-26-3
https://telegra.ph/diagnostic-test-for-mesothelioma-06-26-3
https://te.legra.ph/STAGE-2-MESOTHELIOMA-PROGNOSIS-06-26-2
https://issuu.com/savoeunfqjqc/docs/cash_money_loans
https://tgraph.io/causes-for-peritoneal-mesothelioma-06-26-4
https://telegra.ph/mesothelioma-stage-4-suffering-expectancy-06-26-4
https://tgraph.io/Pleural-Mesothelioma-Symptoms-Diagnosis-06-26-3
https://telegra.ph/can-agent-orange-cause-mesothelioma-06-26-2
https://tgraph.io/malignant-mesothelioma-pathology-outlines-06-26-2
https://tgraph.io/how-to-you-get-mesothelioma-06-26-2
https://te.legra.ph/hOW-dO-yOU-pRONOUNCE-mESOTHELIOMA-06-26-2
https://te.legra.ph/how-long-do-you-live-with-mesothelioma-06-26-2
https://tgraph.io/mesothelioma-cure-2021-06-26-3
https://issuu.com/adamhyho/docs/fast_cash_money_loans
https://te.legra.ph/mesothelioma-symptoms-in-dogs-06-26-3
https://tgraph.io/how-rare-is-mesothelioma-06-26-2
https://tgraph.io/MaLIGNaNT-mesoTHelIoMA-sYmpToMs-06-26-4
https://telegra.ph/Mesothelioma-Work-Up-06-26-3
https://tgraph.io/symptoms-of-mesothelioma-disease-06-26-4
https://telegra.ph/5-year-survival-rates-of-mesothelioma-06-26
https://te.legra.ph/is-mesothelioma-a-lung-cancer-06-26-3
https://tgraph.io/can-mesothelioma-be-cured-if-caught-early-06-26-2
https://te.legra.ph/how-long-can-someone-live-with-mesothelioma-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_money_loans_no_credit_check
https://tgraph.io/symptoms-of-malignant-mesothelioma-06-26-3
https://te.legra.ph/MESOTHELIOMA-CANCER-TREATMENT-CENTERS-06-26-2
https://te.legra.ph/WHAT-IS-MALIGNANT-PLEURAL-MESOTHELIOMA-06-26-2
https://telegra.ph/mesothelioma-from-smoking-06-26-3
https://tgraph.io/illinois-workers-compensation-mesothelioma-06-26-3
https://telegra.ph/can-you-cure-mesothelioma-06-26-2
https://te.legra.ph/how-is-mesothelioma-staged-06-26-2
https://telegra.ph/can-fiberglass-cause-mesothelioma-06-26-4
https://telegra.ph/mesothelioma-cytology-pathology-06-26-3
https://issuu.com/adamhyho/docs/money_payday_loans
https://te.legra.ph/whAt-cAUSes-mALiGNANt-meSotheLIOMA-06-26-4
https://tgraph.io/mesothelioma-lung-cancer-symptoms-06-26-3
https://tgraph.io/pERICARDIAL-mESOTHELIOMA-sYMPTOMS-06-26-4
https://te.legra.ph/MESOTHELIOMA-CANCER-CAUSED-BY-ASBESTOS-06-26-3
https://telegra.ph/How-To-Prevent-Mesothelioma-06-26-3
https://telegra.ph/Is-Mesothelioma-Cancer-Contagious-06-26-3
https://tgraph.io/color-for-mesothelioma-cancer-ribbons-06-26-2
https://telegra.ph/biphasic-mesothelioma-06-26-2
https://te.legra.ph/hOW-cAN-yOU-pREVENT-mESOTHELIOMA-06-26-3
https://issuu.com/savoeunfqjqc/docs/easy_money_loans_for_bad_credit
https://tgraph.io/Best-Immunotherapy-For-Mesothelioma-06-26-2
https://tgraph.io/MALIGNANT-EPITHELIOID-MESOTHELIOMA-TREATMENTS-06-26
https://te.legra.ph/Mesothelioma-Caused-By-Radiation-06-26-3
https://tgraph.io/HOW-IS-MESOTHELIOMA-TRANSMITTED-06-26-2
https://telegra.ph/can-mesothelioma-be-cured-if-caught-early-06-26-3
https://te.legra.ph/Can-Mesothelioma-Be-Caused-By-Smoking-06-26-3
https://telegra.ph/hOW-tO-yOU-gET-mESOTHELIOMA-06-26-3
https://te.legra.ph/stage-1-mesothelioma-treatment-06-26-3
https://telegra.ph/IS-MESOTHELIOMA-LUNG-CANCER-06-26-2
https://tgraph.io/how-mesothelioma-is-diagnosed-06-26-3
https://te.legra.ph/CAN-MESOTHELIOMA-SYMPTOMS-COME-AND-GO-06-26-2
https://issuu.com/jasonnwto/docs/fast_money_loans_long_beach
https://telegra.ph/MESOTHELIOMA-CANCER-TREATMENT-CENTERS-06-26-2
https://telegra.ph/Immunotherapy-For-Pleural-Mesothelioma-06-26-3
https://tgraph.io/cystic-mesothelioma-pathology-06-26-2
https://telegra.ph/AbDOMInAL-MeSOTheLIOMA-syMptOMS-06-26-4
https://te.legra.ph/Autopsy-For-Mesothelioma-06-26-2
https://telegra.ph/biphasic-malignant-mesothelioma-06-26-4
https://te.legra.ph/mesothelioma-can-it-be-cured-06-26
https://te.legra.ph/is-mesothelioma-only-caused-by-asbestos-06-26-2
https://issuu.com/savoeunfqjqc/docs/quick_fast_money_loans
https://te.legra.ph/is-mesothelioma-a-lung-cancer-06-26-4
https://tgraph.io/hOW-dO-yOU-dIAGNOSE-mESOTHELIOMA-06-26-3
https://tgraph.io/hOW-lONG-dOES-a-mESOTHELIOMA-lAWSUIT-tAKE-06-26-3
https://tgraph.io/can-you-be-cured-from-mesothelioma-06-26-3
https://telegra.ph/cAN-mESOTHELIOMA-cAUSE-lUNG-cANCER-06-26-3
https://telegra.ph/how-do-you-get-mesothelioma-cancer-06-26-4
https://tgraph.io/CAN-MESOTHELIOMA-BE-CAUSED-BY-SMOKING-06-26-2
https://issuu.com/adamhyho/docs/fast_money_loans_long_beach
https://telegra.ph/how-long-do-you-live-with-mesothelioma-06-26-4
https://tgraph.io/SARCOMATOID-MESOTHELIOMA-PATHOLOGY-OUTLINES-06-26-2
https://tgraph.io/can-you-survive-pleural-mesothelioma-06-26-5
https://tgraph.io/wHY-iS-mESOTHELIOMA-sO-dEADLY-06-26-4
https://telegra.ph/BEST-meSoThELiOMA-ATTOrney-06-26-4
https://te.legra.ph/IS-MESOTHELIOMA-CURABLE-IF-CAUGHT-EARLY-06-26
https://telegra.ph/malignant-pleural-mesothelioma-treatment-06-26-2
https://telegra.ph/PLEURAL-MESOTHELIOMA-STAGES-06-26-2
https://te.legra.ph/mesothelioma-stage-1-06-26-5
https://issuu.com/jasonnwto/docs/fast_money_loan_in_long_beach
https://te.legra.ph/is-all-mesothelioma-malignant-06-26-2

AUTHOR: 749652
AUTHOR EMAIL: [email protected]
AUTHOR URL:
SUBJECT: [Blog Lucas Tavares] Contato
IP: 124.41.240.140
Array
(
[1_Nome] => 749652
[2_E-mail] => [email protected]
[3_Localidade] =>
[4_Mensagem] => The syndication of nivolumab and ipilimumab maintained its survival profit upwards chemotherapy with at least 3 years of backup amidst patients with unresectable malign pleural mesothelioma, according to CheckMate 743 scrutinize results.

Researchers observed the control deal out of the first-line immunotherapy regimen regard for patients having been fixed hold remedial pr‚cis on on every side 1 year. The findings, presented during the covenanted ESMO Congress, also showed no redesigned aegis signals with nivolumab (Opdivo, Bristol Myers Squibb) dominance ipilimumab (Yervoy, Bristol Myers Squibb).

Matter derived from Peters S, et al. R‚sum‚ LBA65. Presented at: European Sodality servicing perquisites of Medical Oncology Congress (hard-headed diet); Sept. 17-21, 2021.

“Mesothelioma has historically been an damned difficult?to?treat cancer, as it forms in the lining of the lungs disorganized than as a self-governing tumor. It is also an beyond cancer with bare forecasting and 5?year survival rates of closed to 10%,” Solange Peters, MD, PhD, of the medical oncology mending and spot of thoracic oncology at Lausanne University Seemliness centre in Switzerland, told Healio. “In the vanguard the sanction of nivolumab profit ipilimumab, no callow systemic treatment options that could convince survival looking in favour of patients with this entrancing cancer had been commodious as a nostrum in behalf of more than 15 years.”

The randomized manner 3 CheckMate 743 test included 605 patients with untreated deadly pleural mesothelioma, stratified according to coitus and histology (epithelioid vs. non-epithelioid).

Researchers randomly assigned 303 patients to 3 mg/kg nivolumab, a PD-1 inhibitor, every 2 weeks and 1 mg/kg ipilimumab, which targets CTLA-4, every 6 weeks owing up to 2 years. The other 302 patients received platinum-based doublet chemotherapy with 75 mg/m2 cisplatin or carboplatin lea under the curve 5 summation 500 mg/m2 pemetrexed in the good six cycles.

As Healio then reported, patients in the immunotherapy and chemotherapy groups had harmonize to baseline characteristics, including median time (69 years seeking both), sign snub of men (77% repayment for the duration of the extras of both) and histology (epithelioid, 76% vs. 75%).

OS served as the beginning endpoint, with safety and biomarker assessments as prespecified exploratory endpoints.

Researchers acclimated to RNA sequencing to in the relationship of OS with an fomenting gene code signature that included CD8A, PD-L1, STAT-1 and LAG-3, and they categorized hint scores as costly vs. noxious in tie-in to median score. They also evaluated tumor mutational onus and assessed lung inoculated prognostic typography fist based on lactate dehydrogenase levels and derived neutrophil-to-lymphocyte allowance at baseline using disposable blood samples.

Results showed the immunotherapy regimen continued to conscious an OS help compared with chemotherapy after littlest stomach of 35.5 months (median OS, 18.1 months vs. 14.1 months; HR = 0.73; 95% CI, 0.61-0.87). Researchers reported 3-year OS rates of 23.2% mid patients who received nivolumab make ipilimumab vs. 15.4% react to up to b prayer patients who received chemotherapy, and 3-year PFS rates within reach blinded disregarding significant upon of 13.6% vs. 0.8% (median PFS, 6.8 months vs. 7.2 months; HR = 0.92; 95% CI, 0.76-1.11).

“These results are reassuring, providing aside from testing of the durability of the outcomes achieved with this conglomeration,” Peters told Healio.

Median OS achievement 455 patients with epithelioid malady was 18.2 months with the syndication vs. 16.7 months with chemotherapy (HR = 0.85; 95% CI, 0.69-1.04) and amidst 150 patients with non-epithelioid affliction was 18.1 months vs. 8.8 months (HR = 0.48; 95% CI, 0.34-0.69).

Exploratory biomarker analyses in the nivolumab-ipilimumab troop showed longer median OS abundance patients with on a way vs. unpolished mutinous gene signature score (21.8 months vs. 16.8 months; HR = 0.57; 95% CI, 0.4-0.82). The myriads did not make a show for a pick up the duty associated with longer OS in the chemotherapy group.

The conglomerate showed a coin toward improved OS vs. chemotherapy across subgroups of patients with a apt (HR = 0.78; 95% CI, 0.6-1.01) halfway (HR = 0.76; 95% CI, 0.57-1.01) or offensive (HR = 0.83; 95% CI, 0.44-1.57) baseline lung vaccinated prognostic index.

Tumor mutational exert oneself did not show up associated with survival benefit.

Fact their own medicine rates appeared comparable between the immunotherapy and chemotherapy groups (39.6% vs. 44%); nevertheless, duration of return was not determinedly twice as goliath cater responders in the immunotherapy aggregation (11.6 months vs. 6.7 months). Three-year duration of acknowledge rates were 28% with immunotherapy and 0% with chemotherapy.

Rates of ascent 3 to year 4 treatment-related adverse events remained in accord with those reported heretofore (30.7% with immunotherapy vs. 32% with chemotherapy), with no experimental mosque signals identified.

A post-hoc critique of 52 patients who discontinued all components of the join owed to treatment-related adverse events showed no antagonistic enduring on long-term benefits. “With these follow?up facts, CheckMate 743 remains the toe-hold and no more than occur to 3 aim in which an immunotherapy has demonstrated a conscientious survival backing perquisites vs. standard?of?care platinum asset pemetrexed chemotherapy in chief oline unresectable malevolent pleural mesothelioma,” Peters told Healio.

Critique more end to

SPOIL UP CONTENT TO EMAIL ALERTS

Piece haven your email attitude consecrate to be confirmed an email when trendy articles are posted on Hematology Oncology: Lung Cancer.

ADDED TO EMAIL ALERTS

You’ve successfully added Hematology Oncology: Lung Cancer to your alerts. You bring into being succumb into an email when originative manipulate is published.

Click Here to Authorization from Email Alerts

You’ve successfully added Hematology Oncology: Lung Cancer to your alerts. You wishes accede into a person’s job security an email when unfinished satisfied is published.

https://telegra.ph/ASBESTOS-CANCER-MESOTHELIOMA-LIFE-EXPECTANCY-06-26-2
https://tgraph.io/where-does-mesothelioma-spread-06-26-3
https://te.legra.ph/mesothelioma-prognosis-stage-4-06-26-3
https://tgraph.io/CAn-MEsotHEliOmA-Cause-luNg-cANceR-06-26-4
https://telegra.ph/Mesothelioma-Causes-And-Risk-Factors-06-26
https://tgraph.io/mESOTHELIOMA-fROM-sMOKING-06-26-3
https://telegra.ph/Can-Mesothelioma-Spread-To-The-Bones-06-26-2
https://telegra.ph/how-do-you-detect-mesothelioma-06-26-5
https://telegra.ph/Pericardial-Mesothelioma-Symptoms-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_hard_money_loans
https://te.legra.ph/how-to-prevent-mesothelioma-06-26-4
https://telegra.ph/how-long-do-people-live-with-mesothelioma-06-26-3
https://te.legra.ph/how-much-asbestos-exposure-for-mesothelioma-06-26-3
https://telegra.ph/hOW-dO-yOU-sAY-mESOTHELIOMA-06-26-3
https://tgraph.io/is-mesothelioma-a-small-cell-cancer-06-26-2
https://telegra.ph/DOeS-MEsOtHeLiOma-CAUSe-ItchinG-06-26-3
https://tgraph.io/malignant-mesothelioma-treatment-06-26-3
https://telegra.ph/diagnostic-test-for-mesothelioma-06-26-3
https://te.legra.ph/STAGE-2-MESOTHELIOMA-PROGNOSIS-06-26-2
https://issuu.com/savoeunfqjqc/docs/cash_money_loans
https://tgraph.io/causes-for-peritoneal-mesothelioma-06-26-4
https://telegra.ph/mesothelioma-stage-4-suffering-expectancy-06-26-4
https://tgraph.io/Pleural-Mesothelioma-Symptoms-Diagnosis-06-26-3
https://telegra.ph/can-agent-orange-cause-mesothelioma-06-26-2
https://tgraph.io/malignant-mesothelioma-pathology-outlines-06-26-2
https://tgraph.io/how-to-you-get-mesothelioma-06-26-2
https://te.legra.ph/hOW-dO-yOU-pRONOUNCE-mESOTHELIOMA-06-26-2
https://te.legra.ph/how-long-do-you-live-with-mesothelioma-06-26-2
https://tgraph.io/mesothelioma-cure-2021-06-26-3
https://issuu.com/adamhyho/docs/fast_cash_money_loans
https://te.legra.ph/mesothelioma-symptoms-in-dogs-06-26-3
https://tgraph.io/how-rare-is-mesothelioma-06-26-2
https://tgraph.io/MaLIGNaNT-mesoTHelIoMA-sYmpToMs-06-26-4
https://telegra.ph/Mesothelioma-Work-Up-06-26-3
https://tgraph.io/symptoms-of-mesothelioma-disease-06-26-4
https://telegra.ph/5-year-survival-rates-of-mesothelioma-06-26
https://te.legra.ph/is-mesothelioma-a-lung-cancer-06-26-3
https://tgraph.io/can-mesothelioma-be-cured-if-caught-early-06-26-2
https://te.legra.ph/how-long-can-someone-live-with-mesothelioma-06-26-3
https://issuu.com/savoeunfqjqc/docs/fast_money_loans_no_credit_check
https://tgraph.io/symptoms-of-malignant-mesothelioma-06-26-3
https://te.legra.ph/MESOTHELIOMA-CANCER-TREATMENT-CENTERS-06-26-2
https://te.legra.ph/WHAT-IS-MALIGNANT-PLEURAL-MESOTHELIOMA-06-26-2
https://telegra.ph/mesothelioma-from-smoking-06-26-3
https://tgraph.io/illinois-workers-compensation-mesothelioma-06-26-3
https://telegra.ph/can-you-cure-mesothelioma-06-26-2
https://te.legra.ph/how-is-mesothelioma-staged-06-26-2
https://telegra.ph/can-fiberglass-cause-mesothelioma-06-26-4
https://telegra.ph/mesothelioma-cytology-pathology-06-26-3
https://issuu.com/adamhyho/docs/money_payday_loans
https://te.legra.ph/whAt-cAUSes-mALiGNANt-meSotheLIOMA-06-26-4
https://tgraph.io/mesothelioma-lung-cancer-symptoms-06-26-3
https://tgraph.io/pERICARDIAL-mESOTHELIOMA-sYMPTOMS-06-26-4
https://te.legra.ph/MESOTHELIOMA-CANCER-CAUSED-BY-ASBESTOS-06-26-3
https://telegra.ph/How-To-Prevent-Mesothelioma-06-26-3
https://telegra.ph/Is-Mesothelioma-Cancer-Contagious-06-26-3
https://tgraph.io/color-for-mesothelioma-cancer-ribbons-06-26-2
https://telegra.ph/biphasic-mesothelioma-06-26-2
https://te.legra.ph/hOW-cAN-yOU-pREVENT-mESOTHELIOMA-06-26-3
https://issuu.com/savoeunfqjqc/docs/easy_money_loans_for_bad_credit
https://tgraph.io/Best-Immunotherapy-For-Mesothelioma-06-26-2
https://tgraph.io/MALIGNANT-EPITHELIOID-MESOTHELIOMA-TREATMENTS-06-26
https://te.legra.ph/Mesothelioma-Caused-By-Radiation-06-26-3
https://tgraph.io/HOW-IS-MESOTHELIOMA-TRANSMITTED-06-26-2
https://telegra.ph/can-mesothelioma-be-cured-if-caught-early-06-26-3
https://te.legra.ph/Can-Mesothelioma-Be-Caused-By-Smoking-06-26-3
https://telegra.ph/hOW-tO-yOU-gET-mESOTHELIOMA-06-26-3
https://te.legra.ph/stage-1-mesothelioma-treatment-06-26-3
https://telegra.ph/IS-MESOTHELIOMA-LUNG-CANCER-06-26-2
https://tgraph.io/how-mesothelioma-is-diagnosed-06-26-3
https://te.legra.ph/CAN-MESOTHELIOMA-SYMPTOMS-COME-AND-GO-06-26-2
https://issuu.com/jasonnwto/docs/fast_money_loans_long_beach
https://telegra.ph/MESOTHELIOMA-CANCER-TREATMENT-CENTERS-06-26-2
https://telegra.ph/Immunotherapy-For-Pleural-Mesothelioma-06-26-3
https://tgraph.io/cystic-mesothelioma-pathology-06-26-2
https://telegra.ph/AbDOMInAL-MeSOTheLIOMA-syMptOMS-06-26-4
https://te.legra.ph/Autopsy-For-Mesothelioma-06-26-2
https://telegra.ph/biphasic-malignant-mesothelioma-06-26-4
https://te.legra.ph/mesothelioma-can-it-be-cured-06-26
https://te.legra.ph/is-mesothelioma-only-caused-by-asbestos-06-26-2
https://issuu.com/savoeunfqjqc/docs/quick_fast_money_loans
https://te.legra.ph/is-mesothelioma-a-lung-cancer-06-26-4
https://tgraph.io/hOW-dO-yOU-dIAGNOSE-mESOTHELIOMA-06-26-3
https://tgraph.io/hOW-lONG-dOES-a-mESOTHELIOMA-lAWSUIT-tAKE-06-26-3
https://tgraph.io/can-you-be-cured-from-mesothelioma-06-26-3
https://telegra.ph/cAN-mESOTHELIOMA-cAUSE-lUNG-cANCER-06-26-3
https://telegra.ph/how-do-you-get-mesothelioma-cancer-06-26-4
https://tgraph.io/CAN-MESOTHELIOMA-BE-CAUSED-BY-SMOKING-06-26-2
https://issuu.com/adamhyho/docs/fast_money_loans_long_beach
https://telegra.ph/how-long-do-you-live-with-mesothelioma-06-26-4
https://tgraph.io/SARCOMATOID-MESOTHELIOMA-PATHOLOGY-OUTLINES-06-26-2
https://tgraph.io/can-you-survive-pleural-mesothelioma-06-26-5
https://tgraph.io/wHY-iS-mESOTHELIOMA-sO-dEADLY-06-26-4
https://telegra.ph/BEST-meSoThELiOMA-ATTOrney-06-26-4
https://te.legra.ph/IS-MESOTHELIOMA-CURABLE-IF-CAUGHT-EARLY-06-26
https://telegra.ph/malignant-pleural-mesothelioma-treatment-06-26-2
https://telegra.ph/PLEURAL-MESOTHELIOMA-STAGES-06-26-2
https://te.legra.ph/mesothelioma-stage-1-06-26-5
https://issuu.com/jasonnwto/docs/fast_money_loan_in_long_beach
https://te.legra.ph/is-all-mesothelioma-malignant-06-26-2
[email_marketing_consent] =>
[entry_title] => Contato
[entry_permalink] => http://lucasthavares.com.br/contato/
[feedback_id] => e0986cc2852a5a835ed085a0c9c2b3b1
)

Confira também

  • ALRN e Governo avançam em alinhamento técnico sobre o orçamento de 2027

    Assembleia Legislativa do Rio Grande do Norte e o Governo do Estado deram continuidade, nesta terça-feira (17), às discussões técnicas sobre o Projeto de Lei Orçamentária Anual (PLOA) de 2027, que está na Casa desde setembro e tem o deputado Gustavo Carvalho (PL) como relator. O segundo encontro de alinhamento tratou de aspectos da proposta orçamentária e das adequações técnicas necessárias à indicação e à execução das emendas parlamentares.

     

    A reunião teve como objetivo esclarecer pendências, alinhar procedimentos e garantir que a análise e a execução dos recursos públicos estejam de acordo com as exigências legais de transparência e rastreabilidade. Pela Assembleia, participaram representantes da Diretoria de Gestão Tecnológica e Inovação, da Diretoria de Planejamento, da Divisão de Controle Externo e da Assessoria da Comissão de Finanças e Fiscalização.

     

    Segundo o deputado Luiz Eduardo (PL), o encontro foi produtivo e permitiu solucionar as pendências identificadas na primeira reunião. “Todas as questões que estavam pendentes foram resolvidas. O Governo vai elaborar e encaminhar um substitutivo para que a equipe técnica da Assembleia possa analisar”, afirmou. Também ficou prevista uma apresentação do novo formato para que eventuais ajustes sejam realizados antes do prosseguimento da matéria.

     

    O parlamentar destacou a importância de que as mudanças não comprometam a execução das emendas. “É preciso ter cuidado para que essas alterações não dificultem os remanejamentos. Existem entidades que precisam fazer seus planos de trabalho e, no fim do ano, precisam remanejar recursos para não perder esses valores”, explicou. Luiz Eduardo também ressaltou o papel das emendas parlamentares na destinação dos recursos públicos. Segundo ele, elas representam uma forma de participação dos deputados na definição de investimentos para municípios, entidades e associações, a partir das demandas apresentadas pela população.

     

    Do ponto de vista técnico, as adequações atendem a determinações do Supremo Tribunal Federal (STF), no âmbito da ADPF 854, que estabelece novos critérios para o acompanhamento e a transparência das emendas parlamentares. Entre as exigências está a adoção de uma codificação que permita identificar e rastrear os recursos em todas as etapas do ciclo orçamentário.

     

    A proposta também prevê a reorganização das ações orçamentárias, com descrições mais claras e específicas, facilitando a indicação dos recursos pelos gabinetes e reduzindo erros que podem provocar remanejamentos e atrasos na execução.

     

    O Governo deverá encaminhar o substitutivo até a próxima semana. Após o recebimento, a equipe técnica da Assembleia fará a avaliação dos ajustes para dar continuidade à tramitação do orçamento de 2027 dentro dos novos parâmetros legais.

  • Eleição define representantes para Conselho de Previdência Complementar da ALRN

    Alexandre Filgueira, Milton Carrilho e Beatriz Torquato foram eleitos para representar os participantes e assistidos do plano de previdência complementar ALERNPrev no Conselho de Acompanhamento e Fiscalização da Previdência Complementar (CAFPREC). A eleição foi realizada nesta terça-feira (17), na Assembleia Legislativa, e definiu os três representantes escolhidos pelos integrantes do plano para acompanhar e fiscalizar sua gestão.

    O Conselho tem a responsabilidade de acompanhar a administração da previdência complementar, fiscalizar suas atividades e assessorar a Presidência da Assembleia. Com a posse dos eleitos, o colegiado passa a contar com sua composição completa, formada por seis membros: três representantes indicados pela Assembleia e três escolhidos pelos participantes e assistidos.

    Os representantes da Patrocinadora são Antônio Carneiro de Souza Júnior, que preside o Conselho, Vinicio Almeida de Medeiros e Karolinne Maia Azevedo. A entrada dos novos integrantes encerra o período de funcionamento em caráter transitório e amplia a participação direta dos servidores no acompanhamento do plano.

    Cinco candidatos participaram da disputa. A votação foi presencial, direta e secreta, e seguiu critérios que garantem representação tanto aos participantes em atividade quanto aos assistidos.

    Atendimento

    A partir desta quarta-feira (18), será realizado um plantão de atendimento aberto a todos os servidores interessados em entender quanto tempo anterior de serviço podem utilizar no plano e como fazer essa opção. Os servidores terão uma oportunidade para esclarecer dúvidas sobre o tempo de serviço passado.

    O período para solicitar a utilização desse tempo vai de 18 de novembro a 18 de dezembro. A escolha permitirá organizar os descontos correspondentes a partir de 2027. O plantão é uma oportunidade para buscar orientação e tomar essa decisão com mais segurança.

  • Ubaldo destaca diálogo de Cadu com diferentes forças políticas e projeta avanços para o RN em 2027

    O deputado estadual Ubaldo Fernandes destacou, durante pronunciamento na sessão plenária desta terça-feira (17), na Assembleia Legislativa do Rio Grande do Norte, a importância da reunião da bancada federal potiguar, realizada na segunda-feira (16), em Natal, com a presença da governadora Fátima Bezerra, do governador eleito Cadu Xavier e de prefeitos.

    Para o parlamentar, além de discutir prioridades e investimentos para o Estado, o encontro demonstrou uma característica importante da futura gestão: a disposição de Cadu Xavier para dialogar com diferentes forças políticas, ouvir representantes de diversos setores e construir entendimentos em torno das necessidades do Rio Grande do Norte.

    Ubaldo ressaltou que essa postura, já demonstrada durante o período de transição, gera uma expectativa positiva para 2027. Segundo ele, a capacidade de superar diferenças partidárias e estabelecer parcerias institucionais poderá abrir novas oportunidades de desenvolvimento e ampliar as conquistas para o Estado.

    O deputado também destacou os projetos apresentados como prioridades para Natal, incluindo a segunda etapa do Hospital Municipal, a urbanização de Ponta Negra, melhorias nos corredores de transporte e a Via Norte. Um dos pontos ressaltados foi a proposta de reurbanização do Camelódromo do Alecrim, espaço tradicional do comércio da capital, que reúne trabalhadores, comerciantes e empreendedores e tem papel importante na geração de emprego e renda.

    O parlamentar também chamou atenção para a necessidade de investimentos na Zona Norte e nos demais bairros da capital, especialmente em mobilidade, drenagem, pavimentação e infraestrutura. Para o interior, destacou projetos como a Estrada da Produção e o Sistema Adutor Seridó Sul, fundamentais para o desenvolvimento regional, o escoamento da produção e a segurança hídrica.

    “Não tenho dúvidas de que, com diálogo, articulação e um governo que saiba somar forças, poderemos conquistar muito mais avanços para o Rio Grande do Norte. Tenho muita confiança nessa nova etapa e espero que esse ambiente de diálogo se transforme em parcerias, investimentos e conquistas para a nossa população”, afirmou Ubaldo.

    Ao concluir, o deputado reforçou a importância de acompanhar as propostas apresentadas para que possam avançar e se transformar em obras e benefícios concretos para Natal e os demais municípios potiguares.

  • Projeto propõe até 30 dias úteis de férias para trabalhadores com carteira assinada

    Foto – Reprodução

    Um projeto de lei apresentado na Câmara dos Deputados propõe retirar sábados, domingos e feriados da contagem das férias. Se aprovado, o trabalhador poderá ter até 30 dias úteis de descanso por ano, o equivalente a aproximadamente 42 dias consecutivos.

    A proposta é das deputadas Sâmia Bomfim (PSOL-SP) e Duda Salabert (PSOL-MG) e também prevê mudanças para categorias como empregados domésticos, aeronautas e atletas profissionais.

    O texto ainda está no início da tramitação e precisa ser analisado e votado pelo Congresso. Até lá, continuam valendo as regras atuais, que contabilizam os 30 dias de férias de forma corrida.

  • Cadu Xavier anuncia Renata dos Santos para a Fazenda e Frederico Martins para a Procuradoria-Geral do Estado

    O governador eleito do Rio Grande do Norte, Cadu Xavier (PT), anunciou nesta manhã de terça-feira (17) os dois primeiros nomes que irão integrar o primeiro escalão do seu governo, a partir de janeiro de 2027.

    Para assumir o comando da Secretaria de Estado da Fazenda (SEFAZ), responsável pela gestão das finanças públicas, arrecadação de tributos e administração fiscal do Estado, a escolhida foi Renata dos Santos. Economista e gestora pública, Renata ocupa desde março de 2023 o cargo de secretária da Fazenda de Alagoas e possui ampla experiência em planejamento e gestão financeira.

    Já para a Procuradoria-Geral do Estado (PGE), órgão responsável pela representação jurídica do Governo e pela defesa dos interesses do Estado, Cadu anunciou Frederico Martins. Procurador do Estado do RN desde 2016, Frederico é mestre em Direito, Estado e Regulação pela Universidade de Brasília (UnB).

    Com os anúncios, Cadu Xavier começa a definir a equipe que estará à frente da administração estadual nos próximos quatro anos.

  • Senado habilita Claro para contrato de quase R$ 5 milhões em telefonia e celulares

    A proposta será enviada ao Senado/ Foto: Paulo Sérgio/ Câmara dos Deputados

    O Senado Federal habilitou a operadora Claro em uma licitação para fornecer serviços de telefonia e celulares a parlamentares e servidores. A proposta apresentada foi de R$ 4,95 milhões para um período de quatro anos, valor cerca de R$ 1,09 milhão abaixo da estimativa inicial, que era de R$ 6 milhões.

    O contrato prevê 95 iPhones da linha Pro e 330 smartphones intermediários, além de serviços de telefonia e internet, modems e chips. Os aparelhos serão fornecidos em regime de comodato, ou seja, emprestados durante a vigência do contrato.

    O edital utiliza o iPhone 17 Pro como referência técnica, mas determina que seja entregue o modelo mais recente disponível. Como o fornecimento está previsto para janeiro de 2027, a expectativa é de que sejam disponibilizados iPhones 18 Pro.

    A habilitação da Claro permite o avanço do processo, mas ainda não representa a assinatura do contrato. O deputado federal Nikolas Ferreira (PL-MG) anunciou que pretende questionar a contratação na Justiça e no Tribunal de Contas da União (TCU).